REPORT: Second quarter M&A sets 2014 up for a booming year
This article was originally published in Scrip
The amount of pharmaceutical and life science mergers and acquisitions that closed in the second quarter did not exceed the first quarter of 2014, but the number and value of pending deals show that pharma and biotechnology dealmaking isn't about to slow down given the need for companies to expand their portfolios and global reach.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.